TrialHuman vaccines & immunotherapeutics2014

A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers.

Kerstin Westritschnig et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.